Protagonist Therapeutics (PTGX) Retained Earnings (2017 - 2025)
Historic Retained Earnings for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$426.3 million.
- Protagonist Therapeutics' Retained Earnings rose 972.05% to -$426.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$426.3 million, marking a year-over-year increase of 972.05%. This contributed to the annual value of -$340.5 million for FY2024, which is 4469.44% up from last year.
- As of Q3 2025, Protagonist Therapeutics' Retained Earnings stood at -$426.3 million, which was up 972.05% from -$386.9 million recorded in Q2 2025.
- Protagonist Therapeutics' Retained Earnings' 5-year high stood at -$307.8 million during Q1 2021, with a 5-year trough of -$643.0 million in Q3 2023.
- Its 5-year average for Retained Earnings is -$454.4 million, with a median of -$430.3 million in 2022.
- Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 4423.75% in 2021, then soared by 4469.44% in 2024.
- Quarter analysis of 5 years shows Protagonist Therapeutics' Retained Earnings stood at -$409.4 million in 2021, then plummeted by 31.12% to -$536.8 million in 2022, then decreased by 14.71% to -$615.7 million in 2023, then skyrocketed by 44.69% to -$340.5 million in 2024, then decreased by 25.19% to -$426.3 million in 2025.
- Its Retained Earnings was -$426.3 million in Q3 2025, compared to -$386.9 million in Q2 2025 and -$352.2 million in Q1 2025.